Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 18 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes. RESEARCH DESIGN AND METHODS: Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA1c 7–10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, and then 20 μg; n = 120), lixisenatide 1-step (10 μg for 2 weeks and then 20 μg; n = 119), placebo 2-step (n = 61), or placebo 1-step (n = 61) (placebo groups were combined for analyses). Primary end point was HbA1c change from baseline to week 12. RESULTS: Once-daily lixisenatide significantly improved HbA1c (mean baseline 8.0%) in both groups (least squares mean change vs. placebo: −0.54% for 2-step, −0.66% for 1-step; P < 0.0001). Significantly more lixisenatide patients achieved HbA1c <7.0% (52.2% 2-step, 46.5% 1-step) and ≤6.5% (31.9% 2-step, 25.4% 1-step) versus placebo (26.8% and 12.5%, respectively; P < 0.01). Lixisenatide led to marked significant improvements of 2-h postprandial glucose levels and blood glucose excursions measured during a standardized breakfast test. A significant decrease in fasting plasma glucose was observed in both lixisenatide groups versus placebo. Mean decreases in body weight (∼2 kg) were observed in all groups. The most common adverse events were gastrointestinal—nausea was the most frequent (lixisenatide 23% overall, placebo 4.1%). Symptomatic hypoglycemia occurred in 1.7% of lixisenatide and 1.6% of placebo patients, with no severe episodes. Safety/tolerability was similar for the two dose regimens. CONCLUSIONS: Once-daily lixisenatide monotherapy significantly improved glycemic control with a pronounced postprandial effect (75% reduction in glucose excursion) and was safe and well tolerated in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [765]
In the citing paper
“The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Standards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Brown, T., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004095.pub2 · Cited by 351
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350
Ceriello, A., & Colagiuri, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02565.x · Cited by 268
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Self-citationWerner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173
Research works printed but not linked: 3
- Distiller, 2008, Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients (Abstract), Diabetes, 57, A154
- Ratner, 2009, Post-meal pharmacodynamic profile of AVE0010, a once-daily GLP-1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin (Abstract), Diabetologia, 52, S60
- Liu, 2009, Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (Abstract), Diabetes, 59, A149
Cited by
Items 101–200 of 220
Are peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Cai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 28
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
Dar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 28
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Austin, G. O., & Tomás, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170181 · Cited by 25
Becker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12278 · Cited by 25
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 26
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
Hanefeld, M., Arteaga, J. M., Leiter, L. A., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., & Gómez‐Huelgas, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12986 · Cited by 22
Van Gaal, L., Souhami, E., Zhou, T., & Aronson, R. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.03.001 · Cited by 22
Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Deng, W.-Y., Zhao, Z., Zou, T., Kuang, T.-D., & Wang, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421527 · Cited by 23
Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
Leon, N., LaCoursiere, R. J., Yarosh, D., & Patel, R. S. (2017) · PubMed · Cited by 35
Juel, C. T., Lund, A., Andersen, M. M., Hansen, C. P., Storkholm, J. H., Rehfeld, J. F., van Hall, G., Hartmann, B., Albrechtsen, N. J. W., Holst, J. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05158-9 · Cited by 22
Trujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 22
Han, J. D. J., Fei, Y., Zhou, F. L., Chen, X., Zhang, Y., Liu, L., & Fu, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14107 · Cited by 20
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 20
Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day
Ahrén, B., Vorokhobina, N., Souhami, E., Demil, N., Ye, J., & Aronson, R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.05.012 · Cited by 19
Taj, S., Zuber, M., Rashid, M., Chhabra, M., Undela, K., Rawal, S., & Zapata, L. V. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70382 · Cited by 19
Seino, Y., Yabe, D., Takami, A., Niemoeller, E., & Takagi, H. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.003 · Cited by 18
Yabe, D., Ambos, A., Cariou, B., Duvnjak, L. S., Evans, M., González-Gálvez, G., Lin, J., Nikonova, E. V., de Pablos-Velasco, P. L., Yale, J., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.018 · Cited by 18
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 20
Bonadonna, R. C., Blonde, L., Antsiferov, M. B., Berria, R., Gourdy, P., Hatunic, M., Mohan, V., & Horowitz, M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2897 · Cited by 18
Hanefeld, M., Berria, R., Lin, J., Aronson, R., Darmon, P., Evans, M., & Gaal, L. V. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0146-4 · Cited by 18
Bortell, R., Yang, C., Loehn, M., Jurczyk, A., Przewozniak, N., Leehy, L., Herrera, P. L., Shultz, L. D., Greiner, D. L., & Harlan, D. M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s87253 · Cited by 17
Frankel, A., Kazempour‐Ardebili, S., Bedi, R., Chowdhury, T. A., De, P., El‐Sherbini, N., Game, F. L., Gray, S., Hardy, D., James, J., et al. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.073 · Cited by 21
GLP-1 receptor agonists in the treatment of Type 2 diabetes
Bo, A.-R. (2013) · Diabetes Management · doi:10.2217/dmt.13.41 · Cited by 31
Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
Ross, S. A., & Ballantine, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.837817 · Cited by 16
Farngren, J., Persson, M., & Åhrén, B. (2015) · Diabetes Care · doi:10.2337/dc15-1274 · Cited by 18
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Semaglutide: a promising new glucagon-like peptide-1 receptor agonist
Scheen, A. J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30012-8 · Cited by 16
Raccah, D., Gourdy, P., Sagnard, L., & Ceriello, A. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2548 · Cited by 14
Self-citationLixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
Blonde, L., Chava, P., DEX, T. A., Lin, J., Nikonova, E. V., & Goldenberg, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12815 · Cited by 15
González‐González, J. G., González-Colmenero, A. D., Millán-Alanís, J. M., Lytvyn, L., Solís, R. C., Mustafa, R. A., Palmer, S. C., Li, S., Hao, Q., Álvarez‐Villalobos, N. A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049130 · Cited by 16
Moore, M. C., Werner, U., Smith, M. S., Farmer, T. D., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00354.2013 · Cited by 12
Onishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12275 · Cited by 13
Sheng, L., Deng, M., Li, X., Wan, H. Y., Lei, C., Prabahar, K., Hernández‐Wolters, B., & Kord‐Varkaneh, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111617 · Cited by 13
Frank, T. (2013) · Journal of Pharmaceutics & Drug Delivery Research · doi:10.4172/2325-9604.1000112 · Cited by 14
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Cui, X., Meng, Q., Chu, Y., Gu, X., Tang, Y., Zhou, F. L., Fei, Y., Fu, J., & Han, J. D. J. (2016) · RSC Advances · doi:10.1039/c6ra22648e · Cited by 12
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
A drug and disease model for lixisenatide, a GLP‐1 receptor agonist in type 2 diabetes
Wilkins, J. J., Dubar, M., Sébastien, B., & Laveille, C. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.192 · Cited by 12
Raccah, D. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.82 · Cited by 13
Self-citationLixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Aronoff, S. L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285191 · Cited by 11
Management of Metabolic-Associated Fatty Liver Disease
Venkatesan, K., & Haroon, N. N. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.02.002 · Cited by 11
Kim, H. J., Park, S. O., Ko, S., Rhee, S. Y., Hur, K. Y., Kim, N. H., Moon, M. K., Lee, B., Kim, J. H., & Choi, K. M. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.6.423 · Cited by 12
Fisher, M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12380 · Cited by 11
Lu, L., Su, X., Wang, Y., Luo, Y., Yang, J., Li, X., Gao, X., Ma, Y., Tian, Y., Yuan, F., et al. (2017) · RSC Advances · doi:10.1039/c7ra10822b · Cited by 10
Gu, S., Hu, X., Shi, L., Zhen, X., Sun, X., Huang, M., Gu, Y., & Dong, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237094 · Cited by 10
Wilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
Bergenstal, R. M., Strock, E. S., Mazze, R. S., Powers, M. A., Monk, A. M., Richter, S. A., Souhami, E., & Åhrén, B. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2879 · Cited by 8
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
New avenues for the pharmacological management of type 2 diabetes: An update
Cuny, T., Guerci, B., & Cariou, B. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.09.002 · Cited by 7
Shaefer, C. F. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.81 · Cited by 7
Kim, J.-Y., Yang, S., Lee, J. I., & Chang, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153502 · Cited by 7
Seino, Y., Terauchi, Y., Wang, X., Watanabe, D., Niemoeller, E., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12646 · Cited by 7
Ge, G., Dou, H., Yang, S.-S., Ma, J., Cheng, W., Qiao, Z., Hou, Y., & Fang, W. (2015) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(14)60191-7 · Cited by 7
Terauchi, Y., Usami, M., & Inoue, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02121-5 · Cited by 7
Kamalinia, S., Josse, R. G., Donio, P. J., Leduc, L., Shah, B. R., & Tobe, S. W. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.100 · Cited by 7
Specific Activity of Recombinant Modified Human Glucagon-Like Peptide 1
Sannikova, E. P., Bulushova, N. V., Cheperegin, S. E., Zalunin, I. A., Klebanov, F. A., Gracheva, T. S., Yurin, V. L., Rykalina, N. V., Askerova, E. V., Yarotskii, S. V., et al. (2019) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683819070068 · Cited by 8
Baker, D. E., & Levien, T. L. (2017) · Hospital Pharmacy · doi:10.1310/hpj5201-65 · Cited by 6
Broglio, F., Mannucci, E., Napoli, R., Nicolucci, A., Purrello, F., Nikonova, E., Stager, W., & Trevisan, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12810 · Cited by 6
Davidson, J. A., Stager, W., Paranjape, S., Berria, R., & Leiter, L. A. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0088-5 · Cited by 6
Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists
Icart, L. P., de Souza, F. G., & Lima, L. M. T. R. (2021) · Journal of Microencapsulation · doi:10.1080/02652048.2021.1889059 · Cited by 6
Toward Revision of the ‘Best Practice for Diabetic Patients on Hemodialysis 2012’
Abe, M., Matsuoka, T., Kawamoto, S., Miyasato, K., & Kobayashi, H. H. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2040045 · Cited by 7
Htike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Liu, F., Liu, Y., Liu, M., Wu, G., Zhang, M., Zhang, X., Cui, N., Yin, H., & Chen, L. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13504 · Cited by 7
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
Self-citationYamada, Y., Senda, M., Naito, Y., Tamura, M., Watanabe, D., Shuto, Y., & Urita, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12945 · Cited by 6
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedBožek, T., Bilić-Čurčić, I., Berković, M. C., Gradišer, M., Kurir, T. T., Majanović, S. K., & Marušić, S. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0321-x · Cited by 5
When ESKD complicates the management of diabetes mellitus
William, J. H., Morales, A., & Rosas, S. E. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12873 · Cited by 6
Promising areas of pharmacotherapy for obesity
Druzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4279 · Cited by 4
Perfetti, R. (2013) · Diabetes Management · doi:10.2217/dmt.13.51 · Cited by 4
Seino, Y., Stjepanovic, A., Takami, A., Takagi, H., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12686 · Cited by 4
Engeli, S., & Jordan, J. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000449846.91046.ac · Cited by 4
Burcelin, R., & Bertolini, M. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70590-x · Cited by 5
Lixisenatide: clinical profile and available evidence
Dicembrini, I., Bigiarini, M., & Mannucci, E. (2013) · Diabetes Management · doi:10.2217/dmt.13.64 · Cited by 3
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
Li, Y., Tang, L., & Gong, M. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201014666131227120546 · Cited by 3
Shu, H., Gu, L., Men, L., & Lu, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0207-6 · Cited by 4
SKOLNIK, N., Dupree, R. S., & Johnson, E. L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1359518 · Cited by 3
Wei, Z., Wang, M., Zhang, H., Wang, Z., Wang, G.-N., Wei, F., Zhang, Y., Xu, X., & Zhang, Y. (2018) · Medicine · doi:10.1097/md.0000000000013710 · Cited by 3
Abdelhaleem, I. A., Abd‐Elhamied, M. A., Morsi, A. E., & Kenawy, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14602 · Cited by 3
GLP-1R agonists therapy for type 2 diabetes
Zhou, B., Peng, A., Gong, H., & Huang, K. (2014) · Wuhan University Journal of Natural Sciences · doi:10.1007/s11859-014-0974-8 · Cited by 2
Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus
Forst, T. M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1206079 · Cited by 2
Journal of Pharmaceutics & Drug Delivery Research
(2018) · Journal of Pharmaceutics & Drug Delivery Research · doi:10.4172/2325-9604 · Cited by 2
Commercially Available Injectables in Diabetes – Insulin, Incretins, and More
Kesavadev, J., Kalra, S., John, M., Unnikrishnan, A., Joshi, S., Sankar, P., Kumar, A., Jothydev, K., & Basanth, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_29_23 · Cited by 3
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Glucagon like peptide 1 receptor agonists: a therapy for diabetes management
de Antioquia, U., Rojas-Henao, N. A., Granados, J., & de Antioquia, U. (2018) · CES Medicina · doi:10.21615/cesmedicina.32.1.3 · Cited by 1
The Effect of Glucagon-like Peptide-1 (GLP-1) on Obesity
Huang, X., Liang, M., & Wei, B. (2019) · Critical Care Obstetrics and Gynecology · doi:10.21767/2471-9803.1000171 · Cited by 1
Pharmacodynamic Evaluation: Diabetic Methodologies
SANDOW, J. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_33 · Cited by 1
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
Kim, J.-Y., Yang, S., Lee, J. I., & Chang, M. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191744 · Cited by 1
Treatment of obesity: lifestyle and pharmacotherapy
Astrup, A. V. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch33
Hart, N. J. (2013) · UA Campus Repository (The University of Arizona)
Metadata
- Authors
- Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators
- Affiliations
- Tulane University (US)
- Cardioprevent, Durango, Mexico
- Hôpital Sainte-Marguerite (FR)
- Sanofi (France) (FR)
- University of Rochester Medicine (US)
- Corresponding author
- Fonseca, Vivian A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-05-11
- Volume
- 35
- Issue
- 6
- Pages
- 1225-1231
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3357248
- OpenAlex
- W2108122035
- Cited by
- 218
- References
- 21
- Citations by year
- 2025: 5 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 19 · 2017: 27 · 2016: 23 · 2015: 20 · 2014: 31 · 2013: 39 · 2012: 5
- FWCI
- 24.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lixisenatide, GLP-1 receptor agonists, type 2 diabetes, monotherapy, glycemic control, HbA1c, postprandial blood glucose, fasting blood glucose, weight loss, nausea, hypoglycemia, dose escalation, drug safety and tolerability, subcutaneous administration, dyslipidemia
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Adult, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Nausea, Peptides, United States, Blood Glucose Self-Monitoring, Body Mass Index, Treatment Outcome, Postprandial Period, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.